Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 64Breast Neoplasms 15Urinary Bladder Neoplasms 12Colorectal Neoplasms 9Carcinoma, Renal Cell 8Kidney Neoplasms 7Lung Neoplasms 6Neoplasm Metastasis 4Gastrointestinal Neoplasms 4Testicular Neoplasms 3Neoplasms 3Endometrial Neoplasms 3Urogenital Neoplasms 2Urinary Incontinence 2Head and Neck Neoplasms 2Erectile Dysfunction 2Disease 2Depression 2Carcinoma, Transitional Cell 2Anxiety Disorders 2Adenocarcinoma 2Wilms Tumor 1Vomiting 1Varicocele 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Abnormalities 1Urinary Bladder, Overactive 1Thyroid Neoplasms 1

Interventions

pazopanib 2Sunitinib 2Sorafenib 2Bevacizumab 2Surveys and Questionnaires 1Quality Indicators, Health Care 1Immunization, Secondary 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Financial Stress × Surveys and Questionnaires × Genitourinary × Clear all
NCT06955910 2026-05-12

Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.

Istituto Oncologico Veneto IRCCS

Active not recruiting
120 enrolled
Genitourinary

Financial Stress, Urinary Bladder Neoplasms, Kidney Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡